Beyond market averages, investors seeking exceptional growth focus on the art of stock selection. The right picks can significantly contribute to the expansion of your wealth.
Biomarin Pharmaceutical Inc (NASDAQ: BMRN) closed the day trading at $62.53 up 1.63% from the previous closing price of $61.53. In other words, the price has increased by $1.63 from its previous closing price. On the day, 2.3 million shares were traded. BMRN stock price reached its highest trading level at $63.03 during the session, while it also had its lowest trading level at $61.56.
Ratios:
For a better understanding of BMRN, let’s look at its different ratios. It provided that stocks Price–to–Cash (P/C) ratio for the trailing twelve months (TTM) is standing at 12.81 whereas its Price-to-Free Cash Flow (P/FCF) for the term is 37.25. For the most recent quarter (mrq), Quick Ratio is recorded 2.62 and its Current Ratio is at 4.27. In the meantime, Its Debt-to-Equity ratio is 0.11 whereas as Long-Term Debt/Eq ratio is at 0.11.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, Wolfe Research on November 15, 2024, initiated with a Outperform rating and assigned the stock a target price of $95.
Insider Transactions:
The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on Nov 12 ’24 when Guyer Charles Greg sold 5,278 shares for $66.37 per share. The transaction valued at 350,324 led to the insider holds 68,909 shares of the business.
Guyer Charles Greg bought 5,278 shares of BMRN for $350,324 on Nov 12 ’24. On Aug 13 ’24, another insider, Burkhart Erin, who serves as the GVP, Chief Accounting Officer of the company, sold 714 shares for $90.00 each. As a result, the insider received 64,260 and left with 14,449 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, BMRN now has a Market Capitalization of 11917155328 and an Enterprise Value of 11589398528. As of this moment, Biomarin’s Price-to-Earnings (P/E) ratio for their current fiscal year is 37.65, and their Forward P/E ratio for the next fiscal year is 19.43. The expected Price-to-Earnings-to-Growth (PEG) calculation for the next 5 years is 1.88. For the stock, the TTM Price-to-Sale (P/S) ratio is 4.34 while its Price-to-Book (P/B) ratio in mrq is 2.20. Its current Enterprise Value per Revenue stands at 4.21 whereas that against EBITDA is 27.199.
Stock Price History:
The Beta on a monthly basis for BMRN is 0.28, which has changed by -0.33344167 over the last 52 weeks, in comparison to a change of 0.23171377 over the same period for the S&P500. Over the past 52 weeks, BMRN has reached a high of $94.85, while it has fallen to a 52-week low of $60.63. The 50-Day Moving Average of the stock is -4.41%, while the 200-Day Moving Average is calculated to be -18.81%.
Shares Statistics:
Over the past 3-months, BMRN traded about 1.53M shares per day on average, while over the past 10 days, BMRN traded about 1756650 shares per day. A total of 190.55M shares are outstanding, with a floating share count of 188.22M. Insiders hold about 1.24% of the company’s shares, while institutions hold 96.88% stake in the company. Shares short for BMRN as of 1735603200 were 4542138 with a Short Ratio of 2.98, compared to 1732838400 on 5754877. Therefore, it implies a Short% of Shares Outstanding of 4542138 and a Short% of Float of 2.4.
Earnings Estimates
A comprehensive evaluation of Biomarin Pharmaceutical Inc (BMRN) is underway, with the input of 21.0 analysts contributing to its current rating.The consensus estimate for the next quarter is $0.91, with high estimates of $1.06 and low estimates of $0.71.
Analysts are recommending an EPS of between $3.51 and $3.09 for the fiscal current year, implying an average EPS of $3.28. EPS for the following year is $4.15, with 21.0 analysts recommending between $4.87 and $3.58.
Revenue Estimates
26 analysts predict $711.32M in revenue for the current quarter. It ranges from a high estimate of $740M to a low estimate of $680.15M. As of the current estimate, Biomarin Pharmaceutical Inc’s year-ago sales were $646.21MFor the next quarter, 26 analysts are estimating revenue of $729.4M. There is a high estimate of $761.18M for the next quarter, whereas the lowest estimate is $682.44M.
A total of 28 analysts have provided revenue estimates for BMRN’s current fiscal year. The highest revenue estimate was $2.86B, while the lowest revenue estimate was $2.71B, resulting in an average revenue estimate of $2.82B. In the same quarter a year ago, actual revenue was $2.42BBased on 27 analysts’ estimates, the company’s revenue will be $3.11B in the next fiscal year. The high estimate is $3.39B and the low estimate is $2.92B.
